Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705
VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written...
21 Views
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform
VASRO has published an update report on Ainos, Inc. (NASDAQ: AIMD) following the company’s VELDONA licence announcement of 24 September 2026 and...
89 Views
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion
VASRO has published an update report on Ainos, Inc. following the company’s announcement of 14 September 2026.Two facts arrived in the same release.
90 Views
Sirnaomics Ltd: Every Approved SiRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer
VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share. Sirnaomics...
107 Views
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33
VASRO GmbH has published an update report on Baladna Q.P.S.C. (Qatar Stock Exchange: BLDN), reiterating its BUY recommendation with a target price...
104 Views